Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis-Reference-Cited by-同舟云学术

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis

Published:2021-09-07 Issue:1 Volume:37 Page:81-88
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:J of Gastro and Hepatol

Author:

Naganuma Makoto¹^ORCID,Watanabe Kenji²^ORCID,Motoya Satoshi³,Ogata Haruhiko⁴,Matsui Toshiyuki⁵,Suzuki Yasuo⁶,Ursos Lyann⁷,Sakamoto Shigeru⁸^ORCID,Shikamura Mitsuhiro⁹,Hori Tetsuharu⁹,Fernandez Jovelle⁸,Watanabe Mamoru¹⁰,Hibi Toshifumi¹¹,Kanai Takanori¹

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Internal Medicine Keio University School of Medicine Tokyo Japan

2. Department of Intestinal Inflammation Research Hyogo College of Medicine Nishinomiya Japan

3. IBD Center Hokkaido Prefectural Welfare Federation of Agricultural Cooperative, Sapporo‐Kosei General Hospital Sapporo Japan

4. Endoscopic Center Keio University School of Medicine Tokyo Japan

5. Department of Gastroenterology Fukuoka University Chikushi Hospital Chikushino Japan

6. Department of Internal Medicine Toho University Medical Center Sakura Hospital Sakura Japan

7. US Medical Takeda Pharmaceuticals USA, Inc. Deerfield Illinois USA

8. Japan Medical Office Takeda Pharmaceutical Company Limited Tokyo Japan

9. Takeda Development Center Japan Takeda Pharmaceutical Company Limited Osaka Japan

10. Advanced Research Institute Tokyo Medical and Dental University Tokyo Japan

11. Center for Advanced Inflammatory Bowel Disease Research and Treatment Kitasato University Kitasato Institute Hospital Tokyo Japan

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.15667

Reference32 articles.

1. Ulcerative colitis

2. Prevalence of ulcerative colitis and Crohn’s disease in Japan

3. Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

4. Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models

5. Getting to the site of inflammation: the leukocyte adhesion cascade updated

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The alleviative effect of C-phycocyanin peptides against TNBS-induced inflammatory bowel disease in zebrafish via the MAPK/Nrf2 signaling pathways;Fish & Shellfish Immunology;2024-02

2. Comprehensive analysis reveals key genes and environmental toxin exposures underlying treatment response in ulcerative colitis based on in-silico analysis and Mendelian randomization;Aging;2023-12-04

3. Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study;Journal of Crohn's and Colitis;2023-11-29

4. Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study;Annals of Gastroenterology;2023

5. Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis;Biomedicines;2022-10-09